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Nicotine, the primary psychoactive component of tobacco
products, produces diverse neurophysiological, motivational,
and behavioral effects through several brain regions and
neurochemical pathways. Various neurotransmitter systems
have been explored to understand the mechanisms behind
nicotine tolerance, dependence, and withdrawal. Recent
evidence suggests that glutamate neurotransmission has an
important role in this phenomenon. The aim of the present
review is to discuss preclinical findings concerning the role
of N-methyl-D-aspartate (NMDA) receptor neurotransmission
in mediating the behavioral effects of nicotine, tolerance,
sensitization, dependence, and withdrawal. Based on preclinical
findings, it is hypothesized that NMDA receptors mediate the
common adaptive processes that are involved in the
development, maintenance, and expression of nicotine
addiction. Modulation of glutamatergic neurotransmission
with NMDA receptor antagonists may prove to be useful in
alleviating the symptoms of nicotine abstinence and facilitate
tobacco-smoking cessation.
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INTRODUCTION
Tobacco smoking is a powerfully addictive
behavior with underlying addiction to nicotine. It
is far more common than addiction to cocaine,
heroin or alcohol.
1 Nicotine, a natural alkaloid
(1-methyl-2-[3-pyridyl] pyrrolidine) present in
tobacco leaves, is considered to be the major
psychoactive and dependence-producing substance
in tobacco products.
2-5 Like other drugs of abuse,
chronic consumption of nicotine has been shown
to produce both tolerance and dependence in
humans.
1 In recent years, the use of tobacco has
taken a great toll on youth and society. Over three
million smoking related deaths are reported
annually worldwide. It has been projected that
over the coming 30 - 40 years, tobacco will become
the largest single health problem worldwide,
causing 8.4 million deaths annually.
2 Therefore, it
is very important to develop interventions that
can reduce and prevent tobacco use. An under-
standing of the mechanisms by which tobacco
addiction occurs is an essential component of this
goal.
Chronic use of nicotine and other drugs of
abuse leads to three well-known consequences:
tolerance, diminished responsiveness to the same
dose of nicotine; sensitization, an increase in an
effect of a drug with chronic use; and physical
dependence, a neuroadaptive physiological change
resulting from chronic drug exposure, such that
the absence of the drug results in an unpleasant
withdrawal syndrome.
3,4 Since the identification of
nicotine as the primary psychoactive component
of tobacco smoke, a great deal of research has
been undertaken to unravel the neuropharmacolo-
gical, anatomical, and behavioural underpinnings
of its psychoactive effects. Various neural path-
ways and transmitter systems have emerged to
explain the psychoactive and addictive properties
of nicotine. Recent studies suggest those excitatory
amino acid systems and, in particular, N-methyl-
D-aspartate (NMDA) receptors, may have an
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important role in this phenomenon. This review
will focus on recent advances in our understanding
of the role of NMDA receptors in the behavioral
changes that occur following long term nicotine
use, including tolerance, sensitization, and physical
dependence.
NMDA RECEPTORS
Glutamate is a primary excitatory neuro-
transmitter for the majority of CNS receptors and
is involved in the regulation of variety of neural
functions. These receptors have been divided into
two major types: metabotropic and ionotropic,
based on their biochemical, pharmacological, and
molecular profiles.
5 Metabotropic receptors
(mGluRs) are coupled through G-proteins to the
intracellular second-messenger system, whereas
ionotropic glutamate receptors contain ligand-
gated ion channels that mediate rapid changes in
sodium, calcium, and potassium permeability.
Ionotropic receptors are further divided into three
major subtypes: NMDA, -amino-3-hydroxy-5- α
methylisoxazole-4-propionic acid (AMPA), and
kainate, as defined by the affinities of these
synthetic ligands. Of the ionotropic glutamate
receptors, the NMDA subtype has been the most
extensively characterized. The NMDA receptor
consists of a central ion channel and several
modulatory sites to which neurotransmitters and
drugs can bind and affect receptor activity.
6 Key
sites on the receptor include the competitive site,
the glycine site, the noncompetitive site, and the
polyamine site. Each of the binding sites (glutamate,
glycine, polyamine) has been used as a potential
target for the development of both receptor and
sub-type selective compounds.
Binding of an excitatory amino acid to the com-
petitive site on the receptor complex opens the ion
channel and allows entry of calcium ions into the
neuron. When calcium enters the neurons, it can
activate a variety of calcium-dependent enzymes
and thereby modify neuronal function.
7 Competi-
tive antagonists for the NMDA receptor such as
LY274614, AP-7, and CPPP selectively block this
glutamate recognition site. Activation of NMDA
receptors by competitive site agonists requires
coactivation of the glycine site on the complex. In
other words, activation of the receptor by
glutamate is facilitated by the binding of the
co-agonist glycine to an allosteric site on the
receptor complex. The noncompetitive or phency-
clidine (PCP) binding site is located within the ion
channel. Drugs acting at this site such as PCP or
MK-801 block ion movement through the channel
and prevent the influx of calcium, thereby antago-
nizing the activation of the NMDA receptor. The
final key site is the polyamine site. Drugs acting
at the polyamine site noncompetitively affect
receptor activity.
8,9 Studies based on molecular
cloning have shown that the NMDA subtype of
glutamate receptor is a heteromultimeric channel
consisting of NR1, NR2, and NR3 subunits in
various combinations.
10,11 The channel contains
discrete recognition sites for glutamate, glycine,
divalent cations, polyamines, and a site within the
channel. NMDA antagonists are structurally
diverse, and act on these multiple, allosterically
coupled recognition sites.
12 NMDA receptors with
different NR1 and NR2 subunit combinations
have different electrophysiological and pharma-
cological properties.
10 Moreover, the NR1 subunits
are formed from a single gene product with eight
splice variants, whereas NR2 subunits form four
different gene products (NR2A, NR2B, NR2C, and
NR2D).
13 NMDA receptors show distinct distri-
bution patterns in the adult rat brain compared
with the developing brain, suggesting that there
might be different populations of neurons with
unique NMDA receptor subunit compositions and
distinct pharmacological properties.
14,15
It is now well established that NMDA receptors
are widely involved in neural and behavioural
plasticity.
16 NMDA receptors have been implicated
in several different forms of drug-induced neural
and behavioural plasticity, including the develop-
ment of tolerance, sensitization, or physical de-
pendence to a variety of psychoactive drugs
including amphetamine, cocaine, nicotine, ethanol,
benzodiazepines, barbiturates, and cannabinoids.
17-20
At present, a significant number of NMDA
antagonists and modulators are being developed.
Several of those agents are already approved for
clinical use, or are in the late stages (phase II/III)
of clinical trials.
21,22 Moreover, some of the
medications that have been in clinical use for
many years have recently been discovered to haveThe Role of NMDA Receptor Antagonists in Nicotine Tolerance, Sensitization, and Physical Dependence
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some NMDA antagonist properties (e.g. desimi-
pramine, memantine, amantadine, and dextro-
methorphan).
NMDA RECEPTORS AND DEVELOPMENT
OF NICOTINE TOLERANCE
Chronic administration of nicotine results in
tolerance and dependence in both humans and
rodents.
23,24 In the past, the evaluation of nicotine
tolerance and withdrawal has been attempted
using various models, including operant schedules
of reinforcement,
25,26,27 place preference,
28 auditory
startle,
29 and activity,
30 as well as discriminative
stimulus effects of nicotine.
31 However, the
behavioral effects observed in these models in
rodents appear to be complex and varied. The
equivocal results obtained in these studies may be
due to differences in dosage, sex or age of the test
animal, route of drug administration, time of
evaluation, animal strain used, or the behavioral
test employed in the respective study.
32 Nicotine
elicits biphasic inhibitory-stimulatory effects on
locomotion in a baseline-dependent fashion.
33 In
contrast to certain other behavioral effects of
nicotine, tolerance does not appear to develop to
the stimulant and reinforcing actions.
34 The
locomotor stimulant action is rather weak in drug-
naïve animals, and becomes more pronounced
with repeated administration as tolerance develops
to the initial depressant action of the drug.
34
Further, behavioral tolerance develops rapidly
with both acute and chronic administration.
35,36
Morley and Garner have demonstrated that
chronic administration increases locomotor activity
in the light phase, but not in the dark phase, of
the diurnal cycle.
37
Research to date does suggest an interaction
between central nicotinic and dopaminergic
systems.
38 Evidence implicating dopamine in
behavioral effects of nicotine addiction has come
from studies utilizing the neurotoxin 6-hydroxy-
dopamine to produce lesions of forebrain
dopamine systems.
39 In vitro and in vivo studies
show that nicotine can stimulate the release of
dopamine in the ventral tegmental area (VTA),
striatum, and nucleus accumbens.
40,41 These effects
of nicotine also show some selectivity for the
mesolimbic as compared with the nigrostriatal
branch of the dopamine system. It is thought that
the activation of the mesolimbic dopamine system
induced by nicotine underlies the reinforcing and
stimulant effects of this drug.
42 Behavioral studies
with procedures such as drug discrimination
reveal evidence for similarities between the effects
of nicotine and drugs that are known to act as
direct or indirect dopamine agonists.
43 An inter-
pretation of the extinction-like effect of dopamine-
receptor antagonists in terms of impairment of
associative stimulus-reward learning has also
been provided.
44 Further, selective dopamine
antagonists D1 and D2 can also attenuate some of
the behavioral effects of nicotine, including
stimulation of locomotor activity,
45 nicotine self-
administration,
46,47 and the nicotine discriminative
stimulus in rats.
48 Jain et al. studied the effect of
selective dopaminergic drugs in nicotine tolerance
and suggest that tolerance to nicotine may be
mediated through a selective dopamine D2
receptor.
49
The mechanisms by which tolerance to the
effects of nicotine develops are not fully under-
stood. However, biochemical studies have shown
that chronic exposure to nicotine increases high
affinity binding of nicotinic agonists to brain
tissue and induces chronic tolerance to many of
the drug’s behavioral and physiological effects.
50
The increase in receptor number (upregulation)
has been interpreted as a compensation for agonist-
induced desensitization of nicotinic acetylcholine
receptors (nAChRs), and this prolonged desensiti-
zation has been proposed as the mechanism of
chronic tolerance to nicotine.
51,52 Other work has
shown that nicotine exposure over hours to days
upregulates high-affinity nicotine binding to
receptors through a posttranslational mechanism
thought to increase receptor numbers. Nicotine
exposure causes a four to sixfold higher binding
to alpha4beta2 receptors that does not correspond
to any significant change in the number of surface
receptors or a change in the assembly, trafficking,
or cell-surface turnover of the receptors. Such
upregulation might alter the functional state of
the receptors.
53
As noted above, both in vivo and in vitro studies
show that nicotine can release dopamine, but only
a few studies have examined the effects of chronicRaka Jain, et al.
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treatment on this measure. Maisonneuve et al.
demonstrated that single doses of nicotine induce
reversible acute tolerance to nicotine- induced
release in the nucleus accumbens that peaks after
one hour and is lost by three hours after nicotine
administration.
54 This time-course explains the
failure of some studies to observe tolerance
between doses of nicotine repeated over 24
hours.
55,56 Further, the results of the studies
carried out by Blackburn et al. and Carboni et al.
indicate that chronic exposure to nicotine does not
result in complete tolerance to nicotine-induced
stimulation of dopamine release in the nucleus
accumbens.
57,58 These results are apparently at
odds to those of Hildebrand et al., who under
similar conditions did not observe a significant
increase of dialysate conditions.
59
Recently, the effects of NMDA receptor anta-
gonists on tolerance have been extensively studied,
particularly with opiates.
60 Several studies have
also indicated that antagonists acting at various
modulatory sites of the NMDA receptor reduce
tolerance development to the analgesic effects of
opiates.
61 More recently, such inhibitory effects on
the development of morphine tolerance have been
documented for the clinically used compounds
memantine and dextromethorphan.
62,63 NMDA
antagonists also affect tolerance to the effects of
alcohol.
64 The repeated co-administration of
NMDA receptor antagonists MK-801 (dizocilpine) or
D-CPPene (SDZ EAA 494; 3-(2-carboxypiperazin-
4-yl)-1-propenyl-1-phosphonic acid) with nicotine
attenuates the development of tolerance to the
locomotor depressant,
65 and aversive effects of
nicotine in rats.
66 Tolerance to some of the
behavioral effects (learning impairment, ataxia)
also develops when NMDA antagonists are
administered chronically.
67 There are no published
reports on whether cross-tolerance exists between
opioids or psychostimulants and NMDA anta-
gonists. Preliminary data suggest that cross-
tolerance to selected effects exists between NMDA
antagonists and alcohol in laboratory animals.
68,69
Cross-tolerance blockade, as in the case of agonist
substitution therapy, can be very effective in
decreasing drug use and in preventing relapse
following initial exposure in abstinent patients.
In summary, research studies do indicate the
potential role of NMDA receptors in tolerance to
different effects of opiates and ethanol. However,
data from tolerance studies for nicotine have been
limited. Additional studies are needed to under-
stand the role of the NMDA receptor in nicotine
tolerance.
NMDA RECEPTORS AND DEVELOPMENT
OF NICOTINE SENSITIZATION
An alternative phenomenon in addictive behavior
is termed sensitization or reverse tolerance.
Sensitization refers to a progressive enhancement
of species-specific behavioral responses that occurs
with repeated drug administration and typically is
seen in behavioral effects such as locomotor
activity and stereotypy in animals.
70 Recent
evidence suggests that repeated injections of drugs
that lead to locomotor sensitization enhances a
variety of processes related to drug addiction.
71,72
Locomotor sensitization may represent sensitiza-
tion of an underlying reward/incentive system.
73,74
Some of the phenomena manifested in humans
with alcohol and drug dependence (e.g. craving,
impact of environmental stimuli) seem to be
intensified with progressive drug use and there-
fore are believed to be a result of sensitization.
73
These processes may contribute to the maintenance
of a pathological behavior and play a role in
relapse to drug use after a period of abstinence.
Historically, the impetus for studying glutamate’s
role in addiction came from studies of behavioral
sensitization. The long lasting nature of behavioral
sensitization may be attributable to persistently
enhanced responsiveness of neurons that innervate
the nucleus accumbens, such as dopamine neurons
from the VTA and glutamate neurons from the
prefrontal cortex and basolateral amygdala.
75,76
The mechanisms of the adaptive response to
nicotine are not fully understood. Repeated
exposure to nicotine has been shown to cause
behavioral sensitization associated with an
enhanced reactivity of nucleus accumbens dopamine
neurons,
77-79 as well as cross-sensitization to other
addictive drugs.
80,81 However, other studies did
not find such sensitization effects shortly after
repeated nicotine exposure.
82,83 These discordant
findings could be attributable to the time depen-
dence of drug-induced changes.The Role of NMDA Receptor Antagonists in Nicotine Tolerance, Sensitization, and Physical Dependence
Yonsei Med J Vol. 49, No. 2, 2008
Recent evidence suggests that NMDA-mediated
neurotransmission is involved in the development
of behavioral sensitization of psychostimulants,
opioids, and nicotine.
84,85 As reviewed by Wolf,
86
several investigators have found that co-admini-
stration of non-competitive NMDA receptor
antagonists such as dizocilpine (MK-801), during
repeated injections of these addictive drugs
interferes with the development or subsequent
expression of locomotor sensitization. In a series
of experiments, Shoaib, Stolerman, and colleagues
demonstrated that repeated co-administration of
0.3 mg/kg dizocilpine along with 0.4 mg/kg
nicotine during several sensitization sessions
attenuated sensitization to the locomotor stimulant
effect of nicotine.
87,88 This co-administration of
dizocilpine also prevented sensitization of nicotine-
induced dopamine release in the nucleus
accumbens and the sensitized increase in nicotinic
receptors in a variety of areas, including the nucleus
accumbens,
65 that normally occurs with repeated
injections of nicotine. However, pretreatment with
dizocilpine alone caused a modest enhancement
of the behavioural response to a subsequent acute
dose of nicotine. Similarly, co-administration of
another competitive NMDA antagonist, D-CPPene
(2.0 mg/kg), along with 0.4-mg/kg nicotine,
attenuated sensitization to the nicotine-induced
dopamine release in the nucleus accumbens.
There was no enhanced locomotor response that
could be attributed to nicotine pretreatment when
D-CPPene was co-administered with nicotine.
However, pretreatment with D-CPPene alone
enhanced the locomotor response to an acute dose
of nicotine. Although Shoaib et al. interpret this
effect as indicating that dizocilpine has blocked
the development of locomotor sensitization to
nicotine,
65,88 more recent evidence indicates that
similar effects of co-administration of dizocilpine
on the subsequent expression of locomotor
sensitization to other drugs may be due to
state-dependency.
89-91 In other words, animals
repeatedly injected with a combination of dizo-
cilpine/nicotine may become sensitized to the
combination (and to nicotine), but subsequently
fail to express sensitization to nicotine alone, as
nicotine does not sufficiently reproduce the
sensitized dizocilpine/nicotine state. To resolve
this controversy, Kelsey et al. attempted to
determine if the effects of the glutamate NMDA
receptor blocker dizocilpine (MK801) on nicotine
locomotor sensitization are due to a blockade of
the development of sensitization or to state-
dependency.
92 They concluded that co-administra-
tion of a low dose of dizocilpine can block the
development of locomotor sensitization to
repeated injections of nicotine without producing
state-dependency, and thus NMDA receptor
activation appears to be critical for the develop-
ment, but not the subsequent expression, of
nicotine locomotor sensitization. These findings
are in accordance with the studies described
earlier.
87 More recently, Shim and coworkers
studied the role of nitric oxide synthase inhibitors
and NMDA receptor antagonists in nicotine-
induced behavioral sensitization in the rat.
93 They
found that pretreatment with the NMDA receptor
antagonist MK-801 during the nicotine induction
phase also blocked hyperactivity to nicotine
challenge. These results are consistent with
previous data demonstrating that pretreatment
with MK-801 blocks the development of sensitiza-
tion to drugs of abuse including nicotine, cocaine,
amphetamine or methamphetamine.
94 Furthermore,
these results also demonstrate that nicotine-
induced behavioral sensitization requires the
activation of NMDA receptors not only for its
development, but also for its expression. Since
nitric oxide (NO) is known to be formed as a
results of the activation of NMDA receptors,
followed by Ca
2+ influx and stimulation of
Ca
2+/calmodulin-dependent NOS,
95 long-term
behavioral changes produced by nicotine can be
mediated by the activation of NMDA receptors
followed by the formation of NO. Therefore,
blockade of NMDA receptors and NO formation
can result in the development of nicotine-induced
sensitization.
All together, there appears to be general agree-
ment that NMDA receptor antagonists inhibit the
development of nicotine sensitization. NMDA
receptor antagonists have also been found to
inhibit the development of sensitization to the
stimulant effects of other drugs of abuse like
morphine, amphetamine, and cocaine.
4,18,20,70 This
finding indicates that glutamate receptor stimula-
tion is a necessary step in the cascade of cellular
changes leading to sensitization. These results areRaka Jain, et al.
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very intriguing, suggesting that NMDA receptors
may be involved in sensitization to a variety of
different drugs of abuse. Understanding the
mechanisms underlying sensitization is of parti-
cular interest to the field of substance abuse,
because this process may be involved in the
craving that arises from repeated drug exposure.
89
NMDA RECEPTORS AND DEVELOPMENT
OF NICOTINE PHYSICAL DEPENDENCE
Withdrawal from nicotine following chronic use
results in abstinence syndrome, which reaches
peak intensity within 24 hours.
96,97 This syndrome
is characterized by a variety of symptoms including
irritability, anxiety, difficulty concentrating, rest-
lessness, impatience, excessive hunger, insomnia,
drowsiness, and craving for nicotine. Withdrawal
reactions can be elicited either by termination of
chronic administration of the drug or by acute
challenge with the nicotinic receptor antagonist
mecamylamine.
98,99 Evidence suggests rodent
models of nicotine abstinence syndrome are
potentially useful for research to understand the
mechanisms of nicotine dependence and to screen
proposed interventions to aid in smoking cessation.
The few rat models that have been developed rely
upon changes in conditioned behavioral responses
or changes in body weight and food consumption
to measure withdrawal intensity.
100,101 However,
the behavioral response of rodents to nicotine
using these models is complex and varied. As
mentioned above, acute injections of nicotine can
depress locomotor activity,
102 while chronic
administration can increase locomotor activity.
103
Behavioural tolerance rapidly occurs with both
acute and chronic nicotine administration.
104 This
model is based primarily upon the frequency of
spontaneous behavioral signs observed in nicotine-
dependent rats after termination of nicotine.
Abstinence behaviour is characterized by signs
such as teeth chatter, chewing, gasps, abdominal
writhes, body shakes, tremors, ptosis, and seminal
ejaculation.
105 In addition, the administration of
mecamylamine to rats that have been chronically
treated with nicotine using an osmotic minipump
induces various withdrawal signs such as
teeth-chattering, chewing, abdominal wriths, gasps,
ptosis, wet shake, and tremors.
106 Moreover, this
model is similar to widely used rat models of
opiate abstinence syndrome and is analogous to
methods used to quantify nicotine abstinence in
humans.
107,108 In various preclinical studies,
mecamylamine has been used to precipitate an
abstinence syndrome in nicotine-dependent rats.
Mecamylamine has been shown to act as a non-
competitive as well as competitive antagonist to
nicotine.
109-111 It has also been reported to potently
reverse many actions of nicotine including locomotor
effects, tremors,
112,113 analgesia,
114 hypothermia,
115
cardiovascular actions,
116 and effects on operant
behaviour.
117 In addition, mecamylamine potently
attenuates the discriminative stimulus properties
of nicotine in experimental animals and in human
smokers.
118,119
There have been several attempts to clarify the
mechanisms involved in nicotine dependence.
120,121
Nicotine withdrawal precipitates a deficit in brain
reward function, as measured by elevations in
intracranial self-stimulation (ICSS) reward thre-
sholds similar to that observed in rats undergoing
withdrawal from other drugs of abuse.
122
Avoidance and alleviation of this deficit in brain
reward function has been proposed as a motiva-
tional factor contributing to craving, relapse, and
continued tobacco consumption in human
smokers.
97,122 Despite intense investigation into the
mechanisms by which acute nicotine use produces
its rewarding defects, the mechanisms mediating
the reward deficits associated with nicotine
withdrawal remain unclear.
Most drugs of abuse have been shown to
stimulate excitatory glutamatergic transmission
throughout brain reward circuitries.
123 Increase in
glutamatergic transmission has been shown to
play an important role in mediating the positive
reinforcing actions of addictive drugs.
124 Nicotine
is thought to act at several loci within the
mesolimbic system in order to increase dopamine
release within the nucleus accumbens (NAcc) and
thereby produce its rewarding effects.
125,126
Initially, nicotine acts at nAChRs located on
dopamine neurons in the VTA, and increases their
firing rates.
127 Nicotine also acts at presynaptic 7 α
nAChRs located upon glutamate efferents that
arise within the prefrontal cortex (PFC) to increase
glutamate release in the VTA.
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glutamate release then acts at NMDA and non-
NMDA receptor sites on postsynaptic dopamine
neurons and increases their firing rate. Finally,
nicotine also acts at 7 nAChRs located on α
dopamine cell bodies in the VTA and on
presynaptic terminals in the NAcc to increase
dopamine release.
130 Accordingly, blockade of
glutamatergic transmission reduces nicotine’s
stimulatory action on mesoaccumbens dopamine
transmission and attenuates the rewarding actions
of nicotine and other drugs of abuse.
131-133
More recently, it has been documented that
neuroadaptations that occur during prolonged
exposure to drugs of abuse, which give rise to the
deficits in brain reward function associated with
withdrawal, may reside in the same neural
elements that mediate the acute rewarding actions
of these drugs.
134 In contrast to nicotine’s acute
stimulatory effects, however, nicotine withdrawal
attenuates mesoaccumbens dopamine transmis-
sion,
59 an action likely to contribute to the reward
and motivational deficits associated with nicotine
withdrawal.
97 These findings are further supported
by studies carried out by Balfour et al.
27
In addition to its role in mediating the rewarding
effects of drug like nicotine, there is also evidence
that glutamate is involved in drug dependence
and withdrawal states.
135,136 For instance, co-admi-
nistration of the NMDA receptor antagonist MK-
801 blocks the development and/or expression of
opiate,
137 ethanol,
138 and benzodiazepine depen-
dence.
139 Recently, the role of glutamate transmis-
sion, particularly the involvement of metabotropic
glutamate receptors in nicotine withdrawal, has
been investigated. Group II mGluRs are inhibitory
receptors located at presynaptic and postsynaptic
locations.
140 Stimulation of mGluR2/3 decreases
glutamate release throughout the hippocampus,
striatum, and cortex.
141-143 Interestingly, behavioral
experiments with laboratory experiments have
shown that the Group II mGluR selective agonist
LY 354740 ameliorates the increase in acoustic
startle response observed in rats undergoing
nicotine withdrawal.
144 This observation led the
authors to suggest that enhanced glutamate
release may play a role in mediating the aversive
aspects of nicotine withdrawal reflected by an
increase in startle reactivity.
144
It is also noteworthy that acute nicotine
treatment increases the release of glutamate in
various brain sites including the VTA,128 NAcc,77
PFC,
145 and hippocampus,
146 whereas acute
LY354740 decreases glutamate release. In fact,
because withdrawal effects are most often
opposite in direction to acute drug actions,
147 it
might be expected that nicotine withdrawal
would be associated with deficits in glutamate
transmission. It is therefore somewhat surprising
that a drug that acts to decrease glutamate release
ameliorates nicotine withdrawal, particularly
because activation of glutamate receptors plays a
role in mediating the rewarding actions of
nicotine.
148,149 One possible explanation could be
that glutamate release is increased only in certain
brain sites and not in others and that LY 354740
selectively decreases glutamate release involved in
facilitating enhanced startle reactivity. Another
possibility could be that mGluR2/3 may be ex-
pressed on presynaptic terminals that release a
neurotransmitter other than glutamate that
enhances startle reactivity during nicotine with-
drawal.
150,151 Therefore, LY 354740 may act at these
putative mGluR2/3 hetero receptors to block this
release and thereby block the enhanced startle
reactivity observed during nicotine withdrawal.
A more recent review by Balfour also concluded
that repeated nicotine injections increase extra-
cellular dopamine in both the accumbal medial
shell and core and lead to burst firing of
dopaminergic neurons evoked by the drug.
152 This
conclusion is further supported by the observation
that stimulation of NMDA receptors on dopamine
neurons in the VTA enhances the proportion of
the cells that exhibit burst firing.
153 The increases
in dopamine efflux in both the accumbal shell and
core evoked by either acute or repeated nicotine
injections are suppressed or abolished by the
administration of NMDA receptor antagonists
prior to the nicotine injection, suggesting a pivotal
role of glutamate in nicotine’s reinforcing effects.
154
Thus, although the molecular and cellular
mechanisms underlying the response are different,
nicotine shares with amphetamine and cocaine the
ability to elicit a substantial and sustained increase
in dopamine overflow into the extracellular space
between the fibers of the accumbens. It seems
reasonable to conclude that this common response
to the drugs may be of fundamental importanceRaka Jain, et al.
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to their ability to cause dependence.
In summary, like opiate withdrawal syndrome,
nicotine withdrawal syndrome is a complex
phenomenon, characterized by several different
signs and symptoms. Glutamate may play a role
in mediating nicotine withdrawal. Evidence is
lacking to suggest that NMDA receptor antagonists
inhibit the development of nicotine withdrawal
syndrome as a whole or a subset of signs and
symptoms. It will be useful to clarify the impact
of NMDA receptor antagonists on these effects,
both individually and collectively, in order to
better understand the potential role of NMDA
receptors in the development of these different
signs and symptoms and their relationship to one
another.
NMDA receptors and ligands (agonists/anta-
gonists/partial agonists) have been implicated in
the phenomenon of tolerance, dependence, and,
possibly, the management of nicotine dependence.
However, the evidence is still highly equivocal,
and various other neurochemical mechanisms
such as dopamine, cannabinoids, serotonin,
acetylcholine, adrenergics, and GABAergics have
also been implicated in these phenomena. These
receptors and neurotransmitters alone and in
combination with NMDA receptors and ligands
could be the target for development of future
intervention strategies for nicotine dependence.
CONCLUSION
In conclusion, addiction to nicotine is a complex
behavioural phenomenon that produces diverse
neurophysiological, motivational, and behavioural
effects through several brain regions and
neurochemical pathways. In spite of decades of
research, the mechanisms underlying nicotine
tolerance, physical dependence, and withdrawal
are still not well understood and several questions
remain. A substantial amount of preclinical research
suggests the role of glutamatergic, particularly
NMDA receptor, neurotransmission in mediating
the behavioural effects of alcohol and other drugs
of abuse. In animal models, NMDA receptor
antagonists modulate many of the effects of the
chronic administration of psychostimulants, opioids,
benzodiazepines, and alcohol. NMDA antagonists
alleviate physical as well as motivational aspects
of the withdrawal syndrome, attenuate ongoing
drug dependence, and reduce tolerance to several
effects of the drug and to the environment in
which the drug effect was experienced. This
research also supports the therapeutic potential of
NMDA receptor antagonists in alcohol and
substance use disorders. Preclinical research
studies examining the effects of NMDA receptor
antagonists on tolerance, sensitization, and
physical dependence of nicotine, though limited,
are encouraging. These observations suggest that
NMDA receptors are involved in the neural
changes that underlie the development of tolerance,
sensitization, and physical dependence to nicotine.
Hypotheses linking all of the abused substances
and nicotine to a common neural circuit and
dopaminergic neurotransmitter system have also
been suggested. NMDA receptor neurotransmission
may interact with dopaminergic pathways, and
both systems may play a role in mediating the
CNS effects of a variety of substances of abuse,
including nicotine. Moreover, nicotine shares
many of the properties of a psychostimulant drug
of dependence, and it seems reasonable to
conclude that this explains the addictive potential
of the drug and its role in the neurobiology of
tobacco dependence. Furthermore, animal studies
also demonstrate commonalities between nicotine
withdrawal and opiate abstinence syndrome.
Results of preclinial research conducted so far
suggest the therapeutic potential of NMDA
receptor antagonists in alcohol and substance use
disorders. The progress in applying results of
these preclinical studies to the development of
clinical medication has been slow but noteworthy.
Preliminary clinical studies treating opioid
dependence with drugs like dextromethorphan
and memantine in both detoxification and relapse
prevention have been encouraging.
155 The clinical
data regarding the treatment of cocaine dependence
are very limited, although some clinical controlled
studies have demonstrated beneficial effects of
amantadine on cocaine-craving and symptoms of
cocaine withdrawal.
156-158 It is important to
emphasize that amantadine has significant actions
at nicotinic and sigma receptors as well as
enhancement of noradrenergic transmission at the
doses necessary to block NMDA receptors.
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Collins et al. studied the effect of memantine on
cocaine self-administration and suggested that
non-competitive antagonists may potentiate acute
effects of cocaine.
160 Their study has several
limitations, however, and further laboratory
studies and a clinical trial may help to determine
whether memantine will have an advantage over
amantadine for the treatment of cocaine depen-
dence. In addition, NMDA antagonist action of
the naturally occurring alkaloid ibogaine has been
reported, and it has been found to be effective in
the treatment of morphine, heroin, alcohol,
nicotine, and stimulant abuse.
161,162
All together, there are currently a limited
number of available medications to treat nicotine
dependence and other substance abuse disorders.
Despite recent advances in the understanding of
the neurobiological basis of these disorders and
the development of new psychotherapeutic
approaches, a lack of viable pharmacological
treatments persists. It seems likely that most of
the drug therapies introduced to date as aids to
smoking cessation act on some but not all of these
mechanisms, and this explains why none have
proved as efficacious as therapists or smokers
would like. At this stage, it is too early to com-
ment on the potential usefulness of NMDA
receptor antagonists for nicotine dependence.
Several questions remain regarding nicotine
addiction. NMDA receptor antagonists might be
useful as pharmacological adjuncts in the treatment
of nicotine addiction, but further research is
needed.
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